Compare TOUR & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | PDSB |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | China | United States |
| Employees | N/A | 10 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.1M | 62.0M |
| IPO Year | 2014 | 2015 |
| Metric | TOUR | PDSB |
|---|---|---|
| Price | $4.73 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 12.6K | ★ 1.1M |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 17.12% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.30 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.51 |
| 52 Week High | $7.79 | $1.85 |
| Indicator | TOUR | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 33.46 | 49.34 |
| Support Level | $0.68 | $0.91 |
| Resistance Level | $6.50 | $1.12 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | -0.24 | -0.01 |
| Stochastic Oscillator | 0.29 | 42.43 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.